JP Morgan Chase’s BeOne Medicines Ltd ONC Stock Holding History

JP Morgan Chase’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,600	Closed	-$7.41M	–	7808
2025 Q2	$7.41M	Sell	30,600 -12,000	-28%	-$2.94M	﹤0.01%	2803
2025 Q1	$11.6M	Buy	42,600 +30,600	+255%	+$7.15M	﹤0.01%	2411
2024 Q4	$2.22M	Buy	+12,000	New	+$2.45M	﹤0.01%	4076
2020 Q3	–	Sell	-30,000	Closed	-$5.65M	–	5843
2020 Q2	$5.65M	Buy	+30,000	New	+$4.88M	﹤0.01%	2367
2019 Q1	–	Sell	-30,000	Closed	-$4.21M	–	6098
2018 Q4	$4.21M	Buy	+30,000	New	+$3.98M	﹤0.01%	2717
2018 Q3	–	Sell	-18,000	Closed	-$2.77M	–	5863
2018 Q2	$2.77M	Buy	+18,000	New	+$3.21M	﹤0.01%	3151

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase's ONC Position: Q2 2026 in Review

JP Morgan Chase increased its BeOne Medicines Ltd (ONC) stake by 143% in Q2 2026, buying an estimated $32.7M and bringing the position to 188,405 shares worth $54.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1405.

JP Morgan Chase first reported a position in ONC in Q2 2016 and has held it in 36 quarters since. The position peaked at $77.9M in Q2 2021. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

JP Morgan Chase held 188,405 shares of BeOne Medicines Ltd worth $54.6M as of Q2 2026.
JP Morgan Chase bought 110,867 BeOne Medicines Ltd shares in Q2 2026, an estimated $32.7M.
BeOne Medicines Ltd made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1405 holding.
JP Morgan Chase first reported a position in BeOne Medicines Ltd in Q2 2016 and has held it in 36 quarters since.
JP Morgan Chase's BeOne Medicines Ltd position peaked at $77.9M in Q2 2021.
283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.